CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
出版年份 2021 全文链接
标题
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
作者
关键词
-
出版物
NATURE MEDICINE
Volume 27, Issue 8, Pages 1419-1431
出版商
Springer Science and Business Media LLC
发表日期
2021-07-27
DOI
10.1038/s41591-021-01436-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
- (2021) Evan W. Weber et al. SCIENCE
- Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial
- (2021) Matthew J. Frank et al. JOURNAL OF CLINICAL ONCOLOGY
- Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy
- (2020) Nathan Singh et al. BLOOD
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas
- (2020) Jeremy S. Abramson et al. BLOOD
- CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel
- (2020) Sattva S Neelapu et al. BLOOD
- Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia
- (2020) Xin He et al. BLOOD
- Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice
- (2020) Dan Li et al. GASTROENTEROLOGY
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
- (2020) Nirali N. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.
- (2020) Rebecca Alice Gardner et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
- (2020) Kristen Fousek et al. LEUKEMIA
- Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
- (2020) Eugenia Zah et al. Nature Communications
- Tuning the Antigen Density Requirement for CAR T-cell Activity
- (2020) Robbie G. Majzner et al. Cancer Discovery
- Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
- (2020) Travers Ching et al. BMC CANCER
- Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
- (2020) Nirav N. Shah et al. NATURE MEDICINE
- CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma
- (2020) John H Baird et al. BLOOD
- CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
- (2019) Robbie G. Majzner et al. CLINICAL CANCER RESEARCH
- Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells
- (2019) Kevin A. Hay et al. BLOOD
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
- (2019) Persis J Amrolia et al. BLOOD
- Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19
- (2019) Mukta Asnani et al. LEUKEMIA
- c-Jun overexpression in CAR T cells induces exhaustion resistance
- (2019) Rachel C. Lynn et al. NATURE
- Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia
- (2018) Franziska Blaeschke et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
- (2018) Haneen Shalabi et al. HAEMATOLOGICA
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
- (2018) Haneen Shalabi et al. HAEMATOLOGICA
- CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum
- (2018) Asen Bagashev et al. MOLECULAR AND CELLULAR BIOLOGY
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
- (2018) Elena J. Orlando et al. NATURE MEDICINE
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
- (2018) Haiying Qin et al. Molecular Therapy-Oncolytics
- Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
- (2017) Alec J. Walker et al. MOLECULAR THERAPY
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
- (2017) Kevin Bielamowicz et al. NEURO-ONCOLOGY
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma
- (2016) Hui Yu et al. AMERICAN JOURNAL OF HEMATOLOGY
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
- (2016) R. Gardner et al. BLOOD
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- Superior Therapeutic Index in Lymphoma Therapy: CD30 + CD34 + Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack
- (2016) Andreas A Hombach et al. MOLECULAR THERAPY
- CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
- (2016) Elad Jacoby et al. Nature Communications
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
- (2016) E. Zah et al. Cancer Immunology Research
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Characterization of CD22 expression in acute lymphoblastic leukemia
- (2015) Nirali N. Shah et al. PEDIATRIC BLOOD & CANCER
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
- (2014) Y. Xu et al. BLOOD
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+T Cells
- (2014) Keisuke Watanabe et al. JOURNAL OF IMMUNOLOGY
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
- (2013) M. Hudecek et al. CLINICAL CANCER RESEARCH
- Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials
- (2013) Bipulendu Jena et al. PLoS One
- TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
- (2013) Zakaria Grada et al. Molecular Therapy-Nucleic Acids
- Lessons learned from a highly-active CD22-specific chimeric antigen receptor
- (2013) Adrienne H. Long et al. OncoImmunology
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
- (2011) Sara Raponi et al. LEUKEMIA & LYMPHOMA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now